Poll

Poll results: Will you use biosimilars in your ophthalmic practice?

Results from our recent poll indicate that many ophthalmologists (63%) plan to use biosimilars in their clinical practice.

Ophthalmology Times® polled our audience with the following question from September 26, 2022 to October 10, 2022:​ Will you use biosimilars in your ophthalmic practice?

The poll appeared on OphthalmologyTimes.com and was promoted in our e-newsletters during this time. Results show a majority of ophthalmologists plan to use biosimilars in their practice.

37 responses were recorded, in total. Of these:

23% responded, "Yes, I plan to use biosimilars in my practice."

14% responded, "No, I do not plan to use biosimilars in my practice."

.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) NeuroOp Guru: Cranial nerve six palsy with chemosis is a critical clue to cavernous carotid fistula
(Image credit: Ophthalmology Times) Neda Shamie_Controversies in Modern Eye Care 2025
(Image credit: Ophthalmology Times) World Cornea Congress IX: Epi-on and accelerated crosslinking with Kenneth Beckman, MD
(Image credit: Ophthalmology Times) The synergy of cornea, cataract, and refractive surgery through the decades: insights from George O. Waring IV, MD
(Image credit: Ophthalmology Times) AGS 2025: A look at Gemini and the MIGS revolution with Mona Kaleem, MD
(Image credit: Ophthalmology Times) AGS 2025: Development and evaluation of an AI model to set target IOP with Jithin Yohannan, MD, MPH
© 2025 MJH Life Sciences

All rights reserved.